Free Trial
NYSE:IKT

Inhibikase Therapeutics (IKT) Stock Price, News & Analysis

Inhibikase Therapeutics logo
$1.43 -0.12 (-7.74%)
Closing price 08/8/2025 04:00 PM Eastern
Extended Trading
$1.44 +0.01 (+0.35%)
As of 08/8/2025 04:16 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Inhibikase Therapeutics Stock (NYSE:IKT)

Key Stats

Today's Range
$1.42
$1.56
50-Day Range
$1.43
$2.05
52-Week Range
$1.12
$4.20
Volume
142,885 shs
Average Volume
197,512 shs
Market Capitalization
$106.31 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$6.50
Consensus Rating
Moderate Buy

Company Overview

Inhibikase Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
33rd Percentile Overall Score

IKT MarketRank™: 

Inhibikase Therapeutics scored higher than 33% of companies evaluated by MarketBeat, and ranked 761st out of 923 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    Inhibikase Therapeutics has received a consensus rating of Moderate Buy. The company's average rating score is 2.50, and is based on 1 buy rating, 1 hold rating, and no sell ratings.

  • Amount of Analyst Coverage

    Inhibikase Therapeutics has received no research coverage in the past 90 days.

  • Read more about Inhibikase Therapeutics' stock forecast and price target.
  • Earnings Growth

    Earnings for Inhibikase Therapeutics are expected to grow in the coming year, from ($0.97) to ($0.48) per share.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Inhibikase Therapeutics is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Inhibikase Therapeutics is -0.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Inhibikase Therapeutics has a P/B Ratio of 0.80. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Percentage of Shares Shorted

    4.13% of the outstanding shares of Inhibikase Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Inhibikase Therapeutics has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Inhibikase Therapeutics has recently decreased by 5.83%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Inhibikase Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Inhibikase Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    4.13% of the outstanding shares of Inhibikase Therapeutics have been sold short.
  • Short Interest Ratio / Days to Cover

    Inhibikase Therapeutics has a short interest ratio ("days to cover") of 12.5, which indicates bearish sentiment.
  • Change versus previous month

    Short interest in Inhibikase Therapeutics has recently decreased by 5.83%, indicating that investor sentiment is improving significantly.
  • News Coverage This Week

    MarketBeat has tracked 1 news article for Inhibikase Therapeutics this week, compared to 1 article on an average week.
  • Insider Buying vs. Insider Selling

    In the past three months, Inhibikase Therapeutics insiders have not sold or bought any company stock.

  • Percentage Held by Insiders

    Only 7.30% of the stock of Inhibikase Therapeutics is held by insiders.

  • Percentage Held by Institutions

    Only 3.81% of the stock of Inhibikase Therapeutics is held by institutions.

  • Read more about Inhibikase Therapeutics' insider trading history.
Receive IKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Inhibikase Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

IKT Stock News Headlines

IKT Inhibikase Therapeutics, Inc. - Seeking Alpha
Why AMZN, GOOG, MSFT might destroy NVDA
Investing Legend Hints the End May be Near for These 3 Iconic Stocks Futurist Eric Fry say Amazon, Tesla and Nvidia are all on the verge of major disruption. To help protect anyone with money invested in them, he's sharing three exciting stocks to replace them with. He gives away the names and tickers completely free in his brand-new "Sell This, Buy That" broadcast.
See More Headlines

IKT Stock Analysis - Frequently Asked Questions

Inhibikase Therapeutics' stock was trading at $3.25 on January 1st, 2025. Since then, IKT shares have decreased by 56.0% and is now trading at $1.43.

Inhibikase Therapeutics, Inc. (NYSE:IKT) issued its quarterly earnings data on Monday, November, 15th. The company reported ($1.08) EPS for the quarter, missing the consensus estimate of ($0.84) by $0.24. The firm had revenue of $0.33 million for the quarter.

Inhibikase Therapeutics shares reverse split on the morning of Friday, June 30th 2023.The 1-6 reverse split was announced on Friday, June 30th 2023. The number of shares owned by shareholders was adjusted after the market closes on Friday, June 30th 2023. An investor that had 100 shares of stock prior to the reverse split would have 17 shares after the split.

Inhibikase Therapeutics (IKT) raised $15 million in an initial public offering (IPO) on Wednesday, December 23rd 2020. The company issued 1,400,000 shares at a price of $10.00-$12.00 per share. ThinkEquity​ (a division of Fordham Financial Management) served as the underwriter for the IPO.

Inhibikase Therapeutics' top institutional investors include Geode Capital Management LLC (1.43%), Intech Investment Management LLC (0.04%) and Police & Firemen s Retirement System of New Jersey (0.02%). Insiders that own company stock include Milton H Werner and Arvind Kush.
View institutional ownership trends
.

Shares of IKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Inhibikase Therapeutics investors own include Sangamo Therapeutics (SGMO), Advanced Micro Devices (AMD), Meta Platforms (META), NVIDIA (NVDA), CrowdStrike (CRWD) and Intel (INTC).

Company Calendar

Last Earnings
11/15/2021
Today
8/09/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NYSE
Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Pharmaceutical Products
Current Symbol
NYSE:IKT
CIK
1750149
Fax
N/A
Employees
6
Year Founded
N/A

Price Target and Rating

High Price Target
$8.00
Low Price Target
$5.00
Potential Upside/Downside
+354.5%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.50
Research Coverage
2 Analysts

Profitability

EPS (Trailing Twelve Months)
($2.67)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$19.03 million
Net Margins
N/A
Pretax Margin
-22,978.75%
Return on Equity
-350.63%
Return on Assets
-201.82%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
0.85
Quick Ratio
0.85

Sales & Book Value

Annual Sales
N/A
Price / Sales
N/A
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$1.78 per share
Price / Book
0.80

Miscellaneous

Outstanding Shares
74,342,000
Free Float
66,178,000
Market Cap
$106.31 million
Optionable
Not Optionable
Beta
0.90

Social Links

7 Energy Stocks to Buy and Hold Forever Cover

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report

This page (NYSE:IKT) was last updated on 8/9/2025 by MarketBeat.com Staff
From Our Partners